We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-Dose Nevirapine in Previously Untreated Human Immunodeficiency Virus Type 1-Infected Persons Does Not Result in Sustained Suppression of Viral Replication.
- Authors
Jong, M. D. de; Vella, S.; Carr, A.; Boucher, C. A. B.; Imrie, A.; French, M.; Hoy, J.; Sorice, S.; Pauluzzi, S.; Chiodo, F.; Weverling, G. J.; Ende, M. E. van der; Frissen, Ph. J.; Weigel, H. M.; Kauffmann, R. H.; Lange, J. M. A.; Yoon, R.; Moroni, M.; Hoenderdos, E.; Leitz, G.
- Abstract
High-dose nevirapine treatment has been reported to confer sustained antiretroviral effects, despite a rapid development of resistance. The use of this strategy was evaluated in 20 previously untreated human immunodeficiency virus type 1 (HIV-1) p24 antigenemic persons with CD4 cell counts between 100 and 500/mm3. Treatment consisted of 400 mg of nevirapine, after a 2-week lead-in dose of 200 mg. Rash was the most frequently reported adverse event, occurring in 25%. While sustained declines in p24 antigen levels were observed in the majority, serum HIV-1 RNA load and CD4 cell counts returned to baseline values within 12 weeks in virtually all subjects. The resistanceconferring tyrosine-to-cysteine substitution at reverse transcriptase position 181 was detected after 4 weeks in most subjects. These observations suggest that plasma drug levels attained with highdose nevirapine were not sufficient to inhibit nevirapine-resistant virus, although they were ∽2-fold higher than reported IC50 values of resistant virus.
- Publication
Journal of Infectious Diseases, 1997, Vol 175, Issue 4, p966
- ISSN
0022-1899
- Publication type
Article